KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.

ABSTRACT: Promoter methylation represents one of the major epigenetic mechanisms responsible for the regulation of gene expression. Hypomethylating drugs are currently approved for the treatment of myelodysplastic syndromes and acute myeloid leukemia, and some studies have recently been carried out on diffuse large B cell lymphoma (DLBCL). DLBCL is a type of Non‑Hodgkin lymphoma. The aim of the present study was to assess the role of DNA methyltransferase (DNMT)1 in mediating the epigenetic regulation of some key targets previously emerged as hypermethylated in Non‑Hodgkin lymphoma. Reverse transcription‑quantitative PCR, genome‑wide arrays and methylation‑specific PCR were used to determine the level of methylation of specific targets. Gene silencing, gene expression and immunoblotting were used to

SUBMITTER: Frazzi R 

PROVIDER: S-EPMC8600396 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature